Tolrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C16H14F3NO3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 0T93LG5NMK, chemically known as glycine, n-((6-methoxy-5-(trifluoromethyl)-1-naphthalenyl)thioxomethyl)-n-methyl- but more generally known as tolrestat, which bears US NIH Compound Identifier 53359. European Medicines Agency schedules Tolrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11179MIG. The term TOLRESTAT is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 38, No. 6, 1984, List 24) WHO schedules tolrestat in its Anatomical Therapeutic Chemical (ATC) Classification. TOLRESTAT is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations, for tariff and trade purposes, schedule tolrestat under HS 29309085 and SITC 51549. As of Q4 2014, TOLRESTAT remains US FDA's Preferred Term for this commodity. Tolrestat bears US NLM identifiers UMLS ID C0076808 and NCI Concept Code C96310. SMILES: S=C(N(CC(=O)O)C)C1C2C(C(C(OC)CC2)C(F)(F)F)CCC1.